Nivolumab significantly prolonged PFS and OS compared with placebo for patients with [ relapsed mesothelioma ], according to findings presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. “Mesothelioma is predominately a disease that is not suitable … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Cases
➤ GenX Water Contamination Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Ocrevus PML Case Report: Patient Used Ocrevus, Only, Without Prior Tysabri or Gilenya Use
The primary source for this Ocrevus PML case report is a JAMA Neurology Brief Report item dated March 16, 2021, “Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy”. From the Abstract for that medical journal … More
Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma
Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of tumor size in only a minority of patients. Predicting response to chemotherapy in patients with MPM by using a genetic marker would, … More
BIA-ALCL Current Recommendations and Potential Future FDA Guidance Changes
History of BIA-ALCL In 2011, the Food and Drug Administration (FDA) reported 34 cases worldwide of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), bringing this unique disease into the public eye for the first time. Since then, BIA-ALCL has been recognized internationally as … More
Possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in Future
Based on these several recent developments, we expect that there will be an FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in the months to come. The focus of such will likely be these adverse drug events and side effects related to the JAK inhibitors class of drugs: Heart … More
Incidence of mesothelioma and asbestosis by occupation in a diverse workforce
Objective: We sought to characterize detailed patterns of mesothelioma and asbestosis incidence in the workforce as part of an occupational disease surveillance program in Ontario, Canada. Methods: The Occupational Disease Surveillance System (ODSS) cohort was established using workers’ … More